Articles By Alyson Martin
Q&A: What’s Next for Cannabis in Israel?
On the eve of the Israeli election, Cannabis Wire editor Alyson Martin spoke with Israel Cannabis (iCAN) founder Saul Kaye about why the industry is closely watching the US.
DEA Proposes Increase to Research-Grade Cannabis Supply, Again
“This will meet the need created by the increase in the amount of approved research involving marijuana,” the DEA told Cannabis Wire.
Here’s How New York’s Cannabis Companies Lobbied in the Legislature’s Final Days
Curaleaf lobbied on more state bills than any other cannabis company as the session came to a close.
Canopy Growth’s Expanding Lobbying Footprint in the United States
Cannabis Wire has learned that the global company is now lobbying in at least three states.
Here’s What People Want the FDA to Know About CBD
The FDA has been collecting public comments since April to inform CBD product rules, and the window closes tomorrow. From state ag regulators to New York’s Bar Association, here are some highlights.
New York: Adult Use Cannabis Legalization Bill Officially Dead
On the road to the legislative session’s end, legalization at times seemed certain. But consensus among lawmakers, and support in the Senate, fell short.
FDA Extends Public Comment on Products Containing Cannabis
The agency, which will determine the future of the CBD industry, also provided an update on its information gathering. And yesterday, Canada’s health officials initiated a somewhat similar process.
New York’s Nail-Biter: Will “Zombie” Cannabis Legalization Bill Make It?
Today in Albany, the legislative session draws to a close.
Q&A: Do Competing Cannabis Interests Repackage Opioid Research?
A recent cannabis and opioid study highlighted that “corporate actors” with “deep pockets have substantial ability to promote congenial results, as suffering people are desperate for effective solutions.”
